Association of MiR-1247-5p Expression with Clinicopathological Parameters and Prognosis in Breast Cancer

Overview

Journal Int J Exp Pathol

Publisher Wiley

Specialty Pathology

Date 2018 Sep 4

PMID 30175411

Citations 8

Authors

Peng Zhang

Changsheng Fan

Jun Du

Xueli Mo

Qikang Zhao

Affiliations

Soon will be listed here.

Abstract

Our study aimed to clarify the correlation between miR-1247-5p expression and clinicopathological parameters and survival of patients with breast cancer (BC). We evaluated the expression level of miR-1247-5p in 224 formalin-fixed, paraffin-embedded specimens (112 BC and matched cancer free tissues) by quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR). miR-1247-5p expression in BC tissues was found to be decreased compared with matched normal tissues (P < 0.01). Additionally, low miR-1247-5p expression in BC tissues was significantly associated with the advanced TNM stage (P = 0.007), lymph node metastasis (P = 0.015), poorer pathological differentiation (P = 0.005) and molecular subtype (P = 0.027). The patients in the low miR-1247-5p group had a shorter disease-free survival and overall survival than those in the high miR-1247-5p group (P < 0.01). Furthermore, the univariate and the multivariate analyses showed that miR-1247-5p expression was an independent predictor of overall survival (P < 0.01). Our study showed that miR-1247-5p was related to the biological behaviour of breast tumour and prognosis of patients with BC. miR-1247-5p could be a novel tumour suppressor and act as a potential biomarker and therapeutic agent for breast carcinoma.

Citing Articles

Stemness genes and miR-1247-3p expression associate with clinicopathological parameters and prognosis in lung adenocarcinoma.

Limbu S, McCloskey K PLoS One. 2023; 18(11):e0294171.

PMID: 37948380 PMC: 10637681. DOI: 10.1371/journal.pone.0294171.

miR-1247-3p targets STAT5A to inhibit lung adenocarcinoma cell migration and chemotherapy resistance.

Lin J, Zheng X, Tian X, Guan J, Shi H J Cancer. 2022; 13(7):2040-2049.

PMID: 35517418 PMC: 9066213. DOI: 10.7150/jca.65167.

Decreased microRNA-768-3p expression indicates a poor prognosis in patients with breast cancer and promotes breast cancer cell viability, migration and invasion.

Zhou Y, Wang Y, Wang L, Zhang J, Liu X Oncol Lett. 2021; 22(2):579.

PMID: 34122630 PMC: 8190777. DOI: 10.3892/ol.2021.12840.

Identification of MicroRNAs as Diagnostic Biomarkers for Breast Cancer Based on the Cancer Genome Atlas.

Kim J Diagnostics (Basel). 2021; 11(1).

PMID: 33440868 PMC: 7827427. DOI: 10.3390/diagnostics11010107.

Plasma miR-1247-5p, miR-301b-3p and miR-105-5p as potential biomarkers for early diagnosis of non-small cell lung cancer.

Dong X, Chang M, Song X, Ding S, Xie L, Song X Thorac Cancer. 2020; 12(4):539-548.

PMID: 33372399 PMC: 7882392. DOI: 10.1111/1759-7714.13800.

References

Wang K, Li J, Guo H, Xu X, Xiong G, Guan X . MiR-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis. 2012; 33(11):2147-54. DOI: 10.1093/carcin/bgs259. View

Shukla G, Singh J, Barik S . MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol Cell Pharmacol. 2012; 3(3):83-92. PMC: 3315687. View

Singletary S, Allred C, Ashley P, Bassett L, Berry D, Bland K . Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003; 83(4):803-19. DOI: 10.1016/S0039-6109(03)00034-3. View

Mancikova V, Castelblanco E, Pineiro-Yanez E, Perales-Paton J, de Cubas A, Inglada-Perez L . MicroRNA deep-sequencing reveals master regulators of follicular and papillary thyroid tumors. Mod Pathol. 2015; 28(6):748-57. DOI: 10.1038/modpathol.2015.44. View

Agostini A, Brunetti M, Davidson B, Trope C, Heim S, Panagopoulos I . Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression. Oncotarget. 2017; 8(13):21554-21560. PMC: 5400605. DOI: 10.18632/oncotarget.15795. View

Pfaffl M . A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29(9):e45. PMC: 55695. DOI: 10.1093/nar/29.9.e45. View

Ambros V . The functions of animal microRNAs. Nature. 2004; 431(7006):350-5. DOI: 10.1038/nature02871. View

Agarwal S, Hanna J, Sherman M, Figueroa J, Rimm D . Quantitative assessment of miR34a as an independent prognostic marker in breast cancer. Br J Cancer. 2014; 112(1):61-8. PMC: 4453614. DOI: 10.1038/bjc.2014.573. View

Wang J, Raimondo M, Guha S, Chen J, Diao L, Dong X . Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. J Cancer. 2014; 5(8):696-705. PMC: 4174514. DOI: 10.7150/jca.10094. View

10.

Dubey A, Gupta U, Jain S . Breast cancer statistics and prediction methodology: a systematic review and analysis. Asian Pac J Cancer Prev. 2015; 16(10):4237-45. DOI: 10.7314/apjcp.2015.16.10.4237. View

11.

Cinegaglia N, Andrade S, Tokar T, Pinheiro M, Severino F, Oliveira R . Integrative transcriptome analysis identifies deregulated microRNA-transcription factor networks in lung adenocarcinoma. Oncotarget. 2016; 7(20):28920-34. PMC: 5045367. DOI: 10.18632/oncotarget.8713. View

12.

. Breast cancer incidence and death increasing in less-developed countries. Cancer. 2016; 122(3):339. DOI: 10.1002/cncr.29881. View

13.

Musilova K, Mraz M . MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia. 2014; 29(5):1004-17. DOI: 10.1038/leu.2014.351. View

14.

Ben-Dayan M, MacCarthy T, Schlecht N, Belbin T, Childs G, Smith R . Cancer as the Disintegration of Robustness: Population-Level Variance in Gene Expression Identifies Key Differences Between Tobacco- and HPV-Associated Oropharyngeal Carcinogenesis. Arch Pathol Lab Med. 2015; 139(11):1362-72. PMC: 5695554. DOI: 10.5858/arpa.2014-0624-OA. View

15.

Adhami M, Haghdoost A, Sadeghi B, Malekpour Afshar R . Candidate miRNAs in human breast cancer biomarkers: a systematic review. Breast Cancer. 2017; 25(2):198-205. DOI: 10.1007/s12282-017-0814-8. View

16.

Basso D, Gnatta E, Padoan A, Fogar P, Furlanello S, Aita A . PDAC-derived exosomes enrich the microenvironment in MDSCs in a -dependent manner through a new calcium related axis. Oncotarget. 2017; 8(49):84928-84944. PMC: 5689584. DOI: 10.18632/oncotarget.20863. View

17.

Zhang P, Fan C, Du J, Mo X, Zhao Q . Association of miR-1247-5p expression with clinicopathological parameters and prognosis in breast cancer. Int J Exp Pathol. 2018; 99(4):199-205. PMC: 6157300. DOI: 10.1111/iep.12287. View

18.

Abdal Dayem A, Choi H, Yang G, Kim K, Saha S, Cho S . The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular Mechanisms. Nutrients. 2016; 8(9). PMC: 5037565. DOI: 10.3390/nu8090581. View

19.

Li W, Jin X, Zhang Q, Zhang G, Deng X, Ma L . Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol. 2014; 7(6):3287-92. PMC: 4097245. View

20.

Nattinger A . In the clinic. Breast cancer screening and prevention. Ann Intern Med. 2010; 152(7):ITC41. DOI: 10.7326/0003-4819-152-7-201004060-01004. View